Oxymorphone Hydrochloride Tablet
NDC Package 10702-070-06

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Oxymorphone Hydrochloride tablets are indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see Warnings and Precautions ( 5.1)] , reserve oxymorphone hydrochloride tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: Have not been tolerated, or are not expected to be tolerated,Have not provided adequate analgesia or are not expected to provide adequate analgesia. This formulation utilizes a tablet delivery system. Marketed by Kvk-tech, Inc., this product is identified by NDC 10702-070 and is authorized under FDA application ANDA203601.

Identification & Billing

NDC Package Code
10702-070-06
Package Description
60 TABLET in 1 BOTTLE
Product Code
10702-070
11-Digit Billing Format
10702007006
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
60 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Oxymorphone Hydrochloride
Non-Proprietary Name
Oxymorphone Hydrochloride
Substance Name
Oxymorphone Hydrochloride
Dosage Form
Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
OXYMORPHONE HYDROCHLORIDE 5 mg/1
Pharmacologic Class
Usage Information
Oxymorphone hydrochloride tablets are indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see Warnings and Precautions ( 5.1)] , reserve oxymorphone hydrochloride tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: Have not been tolerated, or are not expected to be tolerated,Have not provided adequate analgesia or are not expected to provide adequate analgesia.
DEA Schedule
Schedule II (CII) Substances

Regulatory & Marketing

Labeler Name
Kvk-tech, Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA203601
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
02-11-2013
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (10702-070). Click a package code to view its specific billing and regulatory data.

10702-070-01
100 TABLET in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 10702-070-06 identifies a specific commercial package of 60 tablet in 1 bottle of Oxymorphone Hydrochloride, a human prescription drug labeled by Kvk-tech, Inc.. This tablet is formulated for oral use and contains oxymorphone hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Kvk-tech, Inc. on February 11, 2013. The current certification is valid through December 31, 2027.

How is this Kvk-tech, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 10702007006. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 60 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
10702-070-06
11-Digit CMS (5-4-2)
10702-0070-06

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.